PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide

NCT00744224 · Completed

Last updated 2026-05-28

This clinical trial tested whether a single-day infusion of the medication exenatide could prevent blood sugar problems caused by glucocorticoids in healthy adult men.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 8 people Planned (estimated).

Who can join Ages 18–35 · male only Healthy volunteers accepted.

Timeline Started 2009-02 · est. completion 2010-01

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT00744224 ↗

Description as written by the study sponsor.

The purpose of this study is to explore whether the GLP-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.

Treatments tested

Placebo Drug

Single dose of placebo with saline infusion
Prednisolone Drug

Single dose of 80 mg prednisolone with saline infusion
Prednisolone and Exenatide Drug

Prednisolone 80 mg single dose Exenatide infusion 20 mg/min

Main thing measured	To assess whether a single day infusion of the GLP-1 RA exenatide, as compared to placebo, reverses GC-induced impairment of glucose metabolism in healthy males, quantified as glucose tolerance (AUCgluc) during a standardized mixed-meal test
Sponsor	Amsterdam UMC, location VUmc
Conditions studied	Glucocorticoid-induced Glucometabolic Abnormalities, Glucocorticoid-induced Beta-cell Dysfunction
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00744224 ↗